Skip to content

DBV Technologies DBVT Cash & Equivalents

Cash & Equivalents at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$25.32M-79.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$75.08M-2.1%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$35.73M+109%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$144.09M+60.2%
Alumis Inc. logo
Alumis Inc.ALMS
$63.89M-50.3%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
Enterprise value$700.21M+179%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's cash & equivalents?
DBV Technologies (DBVT) reported cash & equivalents of $229.2M in Q1 2026.
How has DBV Technologies's cash & equivalents changed year-over-year?
DBV Technologies's cash & equivalents increased by 1668.2% year-over-year, from $12.96M to $229.2M.
What is the long-term trend for DBV Technologies's cash & equivalents?
Over 5 years (2020 to 2025), DBV Technologies's cash & equivalents has grown at a -0.2% compound annual growth rate (CAGR), from $196.35M to $194.2M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.